A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma

Prior treatment

• Patients with prior embolization or other local treatments within 28 days before enrollment, or needing combined local treatment with TACE;
• Received other antitumor systemic treatment within 28 days before enrollment;
• Received blood products or certain corrective treatments within 7 days before enrollment;
• Participation in other clinical trials within 28 days before enrollment;

Other illness

• Severe allergies to contrast agents or embolization materials;
• Factors affecting study results or necessitating study termination (alcoholism, drug abuse, severe diseases);
• Severe infections unsuitable for TACE;

Lab values

• Abnormal blood counts (WBC, platelets, neutrophils, hemoglobin);
• Abnormal liver function tests (bilirubin, enzymes, albumin);
• Renal impairment (creatinine, creatinine clearance);

Other

• Unsuitable for TACE due to lesion characteristics or vascular issues;
• Vp3/Vp4 portal vein tumor thrombus;
• Tumor occupying ≥70% of liver volume;
• Decompensated cirrhosis or recent ascites drainage/TIPS;
• Prolonged PT;
• Unsuitable feeding artery for TACE or embolization risks;
• Expected survival \<6 months;
• Pregnant, lactating, or planning pregnancy;
• Other reasons deemed unsuitable by the investigator.

• Age range: 18 to 80 years inclusive, regardless of gender;
• Patients with primary hepatocellular carcinoma (HCC) at CNLC stage Ib to IIIa who require transarterial chemoembolization (TACE) treatment and are unsuitable for or refuse surgical resection, liver transplantation, and ablation therapy;
• ECOG score ≤ 2, and Child-Pugh classification of A or B;
• Presence of at least one untreated, measurable tumor lesion with a diameter ≥ 3.0 cm according to mRECIST criteria (the maximum diameter of the target lesion ≤ 10.0 cm);
• Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection who are willing to receive antiviral treatment throughout the study period;
• Voluntary participation in this clinical trial and signing of the informed consent form by the subject.